Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study

Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study

HUANG Zhuhang, HE Jianfeng, SU Jiali, OU Zhiqiang, LIU Guixiu, FU Rong, SHOU Qiong, ZHENG Minghuan, Thomas Group, Alain Luxembourg, LIAO Xueyan, ZHANG Jikai

Chinese Journal of Clinical Obstetrics and Gynecology ›› 2022, Vol. 23 ›› Issue (1) : 4-8. DOI: 10.13390/j.issn.1672-1861.2022.01.002

Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in Chinese females aged 9 to 26 years: A phase 3, open-label, immunobridging study

{{article.zuoZhe_EN}}

Author information +

History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

Download Citations

{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2022, 23(1): 4-8 https://doi.org/10.13390/j.issn.1672-1861.2022.01.002

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}

{{article.copyrightLicense_en}}

Accesses

Citation

Detail

Sections

Recommended

/

〈

〉